Activity of two different triazoles in a murine model of paracoccidioidomycosis

ABSTRACT

A new orally absorbable triazole (Schering 39304) with a long serum half-life in man (60 hours), was tried in a murine model of progressive paracoccidioidomycosis and compared with itraconazole, another triazole which has proven effective in this mycosis. Only 15 of the infected, untreated mice survived while 53 to 75 of the animals receiving itraconazole survived. Mice treated with Schering 39304 exhibited higher (86-100) survival rates. Statistically, the 5 mg/kg Sch 39304 was superior to the 50 mg/kg itraconazole dose. Lung cultures showed that 20 mg/kg/day of Sch achieved sterilization of the infectious foci. These results indicate that the new triazole will have a place in the treatment of paracoccidioidomycosis.